Penumbra Inc
Research Penumbra Inc (PEN) on Bullrun: valuation model: 9.2% undervalued, market cap USD 12.78B, P/E 79.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPEN
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal9.2% undervalued
- Market capUSD 12.78B
- P/E79.7
- Financial periodQ2 2026
- RevenueUSD 390.05M
- Net incomeUSD 34.81M
- Free cash flowUSD 32.54M
- Gross margin67.9%
Valuation Snapshot
Bullrun's latest valuation model marks Penumbra Inc as 9.2% undervalued; latest market cap is USD 12.78B; P/E is 79.7.
Peer valuation comparison
Latest P/E is 79.66x versus a Healthcare sector median of 24.46x (225.7% above).
Latest P/E is 79.66x versus a United States median of 24.87x (220.3% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.40B | USD 177.69M | USD 174.93M | 67.1% | 4.52 | USD 186.90M | USD 219.70M | USD 1.43B |
| FY2024 | USD 1.19B | USD 14.01M | USD 147.30M | 63.2% | 0.36 | USD 324.40M | USD 223.39M | USD 1.15B |
| FY2023 | USD 1.06B | USD 90.95M | USD 82.12M | 64.5% | 2.32 | USD 167.49M | USD 234.34M | USD 1.18B |
| FY2022 | USD 847.13M | -USD 2.00M | -USD 74.96M | 63.2% | -0.05 | USD 69.86M | USD 219.91M | USD 998.86M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 12.78B | 79.7 | n/a | n/a |
| 2025 | 2025-12-31 | USD 12.20B | 68.8 | n/a | n/a |
| 2024 | 2024-12-31 | USD 9.14B | 698.5 | n/a | n/a |
| 2023 | 2023-12-29 | USD 9.71B | 241.9 | n/a | n/a |
| 2022 | 2022-12-30 | USD 8.45B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 10.80B | 2052.3 | n/a | n/a |
About Penumbra Inc
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Penumbra Inc overvalued or undervalued?
Bullrun's valuation model currently marks Penumbra Inc as 9.2% undervalued.
What is Penumbra Inc's market cap?
Penumbra Inc's market capitalization is USD 12.78B.
What is Penumbra Inc's P/E ratio?
Penumbra Inc's price-to-earnings (P/E) ratio is 79.7.
What does Penumbra Inc do?
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.